contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Antti Siltanen

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Once again, several messages have been posted to this thread that hold practically no value from the perspective of investing in Faron. And here’s one more of those. Regarding this discussion about Karvonen’s ownership, perhaps Faron’s website could include a clarification under management holdings that the ownership also includes controlled entities. As for whether the absence of such a clarification has any significance, I don’t think so.

Yeah, you spoke about sales (hearsay - not fact), not holdings. And you claimed that the sales haven’t been reported (your own interpretation - not fact). Well, enough of this.

You are right. There wouldn’t be anything unclear about this if care was taken to ensure that the information is up to date and in an understandable format. I’m mostly kicking myself because checking the unclear situation of just one person would not have been a difficult task.

Everyone can draw their own conclusions. @Donkey said they had checked the holdings from Euroclear and Karvonen’s name was not found there, so their “hearsay” proved to be a fact following Karvonen’s statement. Thus, Karvonen’s name is still not found in the shareholder register, as he does not own the shares. Faron, Karvonen, or anyone else cannot expect anyone to read the 2024 share issue prospectus to verify the matter, as I already stated above. Faron could easily fix this if they wanted to, by reporting the holdings exactly as they appear in Euroclear.

You lumped all sorts of things together earlier, neatly turning rumors into facts regarding, for example, Karvonen’s “sales” and Faron’s breach of disclosure obligations. Now you’re blaming Faron’s communication for the fact that the bottom fell out of your rumor-mongering. That deflection is quite Trumpian, indeed. Perhaps you could focus more on fact-checking instead of just churning out others’ “findings” as half-truths—if, that is, you want to be making these kinds of summaries at all…

I wouldn’t count this as your mistake; rather, I think this falls on Faron’s reporting. Shareholdings are public information, and everyone can check them from Euroclear practically in real-time. However, Faron does not display this ownership information as is on its own website, and I ask for the umpteenth time: Why not? There is no mention of Karvonen’s affiliations and controlled entities on the company’s website, but he is reported to own 104,000 shares:  Neither Faron nor anyone else can expect that someone would go looking for this information in the 2024 offering prospectus. For example, in Karvonen’s case, an easy solution would be to show that company as an owner and, in the additional information—or at least in the information detailing management holdings—state that it is Karvonen’s controlled entity. The actual state of Syrjälä’s, and indeed everyone else’s holdings, seems questionable when Faron modifies them from Euroclear’s official data according to its own criteria.

Currently, cash is being preserved by diluting shareholdings through an increase in the number of shares while repaying debt with additional shares. Before the March general meeting, Faron aims to maximize its negotiating position by publishing expanded data (such as the BEXAR and BLAZE study updates in solid tumors at the end of January). The goal is to create “competitive tension” toward Big Pharma and demonstrate that bexmarilimab is Phase 3-ready. At this stage, the company needs either a letter of intent (LOI) or concrete signs of an upfront payment to be able to present something other than a survival model to the general meeting. The general meeting on March 30, 2026, acts as a deadline where the company’s board must obtain new, broad authorizations for share issues and potentially for drawing the third debt tranche if a partnership agreement has not yet been signed. A hypothesis could be that authorizations are sought at the general meeting to enable either a large directed issue (institutions) or the finalization of a partnership deal. The meeting is, at least for me as an investor, a kind of crossroads: it will be either the formalization of a rescue operation or a major moment of celebration accompanied by a newly announced mega-deal. I suppose one could create an infinite number of hypotheses?

Faron Pharmaceuticals

Faron Pharmaceuticals is a clinical stage biopharmaceutical company whose three drug candidates relate to the modulation of immune system or inflammatory response. Faron is a very high-risk ...

<p>Faron Pharmaceuticals is a clinical stage biopharmaceutical company whose three drug candidates relate to the modulation of immune system or inflammatory response. Faron is a very high-risk investment as drug development requires frontloaded investments in research, while the success of commercialization is very uncertain. If the drug candidates enter the market, the invested capital can be multiplied. However, failure of drug development is frequent and, in that case, the invested capital may be partially or totally lost. We believe the share provides sufficient expected return to counterbalance the high risk. The share is suitable for a long-term investor that tolerates high risk as part of a well-diversified portfolio. A person investing in Faron must also be prepared for share issues.</p> 

	2021	22e	23e
Revenue	0.0	0.0	0.0
growth-%
EBIT (adj.)	-21.1	-22.0	-0.8
EBIT-% (adj.)	-527,700.0 %	-550,000.0 %	-19,500.0 %
EPS (adj.)	-0.40	-0.40	-0.02
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Risky investment with huge potential

Key Estimate Figures2022-08-08

Forum discussions